$OPRX
OptimizeRx Corp Stock $oprx

$oprx Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000121390023067120 Filed on August 14, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$16.33M	$13.82M	$13.98M
YoY Change	8.26%	-1.15%	2.59%
Cost Of Revenue	$6.531M	$5.993M	$4.989M
YoY Change	15.3%	20.13%	-10.61%
Gross Profit	$9.800M	$7.825M	$8.990M
YoY Change	4.03%	-12.96%	11.75%
Gross Profit Margin	60.01%	56.63%	64.31%
Selling, General & Admin	$12.89M	$12.24M	$12.32M
YoY Change	238.13%	-0.63%	79.35%
% of Gross Profit	131.5%	156.45%	137.05%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$470.0K	$464.8K	$578.1K
YoY Change	-8.88%	-19.61%	10.3%
% of Gross Profit	4.8%	5.94%	6.43%
Operating Expenses	$13.35M	$12.71M	$12.90M
YoY Change	1.34%	-1.49%	67.41%
Operating Profit	-$3.553M	-$4.882M	-$3.909M
YoY Change	-5.41%	24.9%	-1249.09%
Interest Expense	$690.0K	$720.4K	$23.82K
YoY Change	137.96%	2924.43%	99.16%
% of Operating Profit
Other Income/Expense, Net	$688.2K	$720.4K	$23.82K
YoY Change	137.33%	2924.94%
Pretax Income	-$2.865M	-$4.161M	-$3.885M
YoY Change	-17.35%	7.12%	-1203.3%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$2.865M	-$4.161M	-$3.885M
YoY Change	-17.35%	7.12%	-1203.3%
Net Earnings / Revenue	-17.54%	-30.12%	-27.79%
Basic Earnings Per Share	-$0.17	-$0.24	-$0.21
Diluted Earnings Per Share	-$0.17	-$0.24	-$214.4K
COMMON SHARES
Basic Shares Outstanding	16.64M shares	17.13M shares	18.12M shares
Diluted Shares Outstanding	16.64M shares	16.99M shares	18.12M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$63.50M	$62.74M	$87.39M
YoY Change	-19.41%	-28.21%	4.13%
Cash & Equivalents	$9.921M	$9.808M	$87.39M
Short-Term Investments	$53.60M	$52.93M
Other Short-Term Assets	$3.000M	$4.053M	$4.281M
YoY Change	10.17%	-5.33%	37.01%
Inventory
Prepaid Expenses	$3.009M
Receivables	$20.84M	$18.28M	$18.73M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$87.39M	$85.07M	$110.4M
YoY Change	-12.02%	-22.94%	5.17%
LONG-TERM ASSETS
Property, Plant & Equipment	$149.3K	$141.0K	$421.9K
YoY Change	3.62%	-66.58%	-20.45%
Goodwill	$22.67M	$22.67M
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.100M		$12.86K
YoY Change	8453.65%		0.0%
Total Long-Term Assets	$36.54M	$36.25M	$37.04M
YoY Change	0.0%	-2.13%	39.04%
TOTAL ASSETS
Total Short-Term Assets	$87.39M	$85.07M	$110.4M
Total Long-Term Assets	$36.54M	$36.25M	$37.04M
Total Assets	$123.9M	$121.3M	$147.4M
YoY Change	-8.79%	-17.72%	12.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$700.0K	$817.8K	$1.296M
YoY Change	-30.04%	-36.9%	60.91%
Accrued Expenses	$3.109M	$1.503M	$1.726M
YoY Change	82.92%	-12.92%	-21.49%
Deferred Revenue	$188.0K	$451.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.702M	$5.510M	$6.441M
YoY Change	25.55%	-14.46%	-3.36%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$100.0K	$0.00	$189.8K
YoY Change	-40.03%	-100.0%	-32.92%
Total Long-Term Liabilities	$100.0K	$0.00	$189.8K
YoY Change		-100.0%	-32.92%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.702M	$5.510M	$6.441M
Total Long-Term Liabilities	$100.0K	$0.00	$189.8K
Total Liabilities	$7.822M	$5.510M	$6.631M
YoY Change	24.14%	-16.91%	-4.56%
SHAREHOLDERS EQUITY
Retained Earnings	-$60.12M	-$57.25M
YoY Change	29.66%
Common Stock	$18.39K	$18.38K
YoY Change	0.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.741K	$1.741K
YoY Change	146.6%
Treasury Stock Shares
Shareholders Equity	$116.1M	$115.8M	$140.8M
YoY Change
Total Liabilities & Shareholders Equity	$123.9M	$121.3M	$147.4M
YoY Change	-8.79%	-17.72%	12.02%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$2.865M	-$4.161M	-$3.885M
YoY Change	-17.35%	7.12%	-1203.3%
Depreciation, Depletion And Amortization	$470.0K	$464.8K	$578.1K
YoY Change	-8.88%	-19.61%	10.3%
Cash From Operating Activities	$1.470M	-$2.368M	$308.1K
YoY Change	-57.54%	-868.56%	65.97%
INVESTING ACTIVITIES
Capital Expenditures	$320.0K	$1.103M	-$26.86K
YoY Change	-1471.62%	-4207.56%	-173.89%
Acquisitions
YoY Change
Other Investing Activities	-$690.0K	$4.326M	-$2.094M
YoY Change	-98.16%	-306.61%	1084.25%
Cash From Investing Activities	-$1.010M	$3.223M	-$2.121M
YoY Change	-97.31%	-251.97%	1409.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$251.3K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-350.0K	-7.490M	251.3K
YoY Change	-97.09%	-3080.74%	-84.21%
NET CHANGE
Cash From Operating Activities	1.470M	-2.368M	308.1K
Cash From Investing Activities	-1.010M	3.223M	-2.121M
Cash From Financing Activities	-350.0K	-7.490M	251.3K
Net Change In Cash	110.0K	-6.635M	-1.561M
YoY Change	-100.24%	324.96%	-195.4%
FREE CASH FLOW
Cash From Operating Activities	$1.470M	-$2.368M	$308.1K
Capital Expenditures	$320.0K	$1.103M	-$26.86K
Free Cash Flow	$1.150M	-$3.471M	$335.0K
YoY Change	-67.01%	-1136.28%	124.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2023Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation		usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18281133	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22155301	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4052729	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2280828	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	85074023	usd
CY2023Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38543
	dei	Entity Registrant Name EntityRegistrantName	OptimizeRx Corporation
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1265381
	dei	Entity Address Address Line1 EntityAddressAddressLine1	260 Charles Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 302
	dei	Entity Address City Or Town EntityAddressCityOrTown	Waltham
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02453
	dei	City Area Code CityAreaCode	248
	dei	Local Phone Number LocalPhoneNumber	651-6568
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001
	dei	Trading Symbol TradingSymbol	OPRX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16637891	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9808330	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18208685	usd
CY2023Q2	us-gaap	Short Term Investments ShortTermInvestments	52931831	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	55931821	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	98576635	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	140968	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	137448	usd
CY2023Q2	us-gaap	Goodwill Goodwill	22673820	usd
CY2022Q4	us-gaap	Goodwill Goodwill	22673820	usd
CY2023Q2	oprx	Technology Assets Net TechnologyAssetsNet	8366375	usd
CY2022Q4	oprx	Technology Assets Net TechnologyAssetsNet	7702895	usd
CY2023Q2	us-gaap	Mineral Properties Net MineralPropertiesNet	1831839	usd
CY2022Q4	us-gaap	Mineral Properties Net MineralPropertiesNet	1940178	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14544	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	235320	usd
CY2023Q2	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	3223305	usd
CY2022Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	3384889	usd
CY2023Q2	us-gaap	Other Assets OtherAssets	36109883	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	35937102	usd
CY2023Q2	us-gaap	Assets Assets	121324874	usd
CY2022Q4	us-gaap	Assets Assets	134651185	usd
CY2023Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	817779	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1549979	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1503477	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2601246	usd
CY2023Q2	oprx	Revenue Share Payable Current RevenueSharePayableCurrent	2722127	usd
CY2022Q4	oprx	Revenue Share Payable Current RevenueSharePayableCurrent	3990440	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	14545	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	89902	usd
CY2023Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	451787	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	164309	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5509715	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8395876	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	144532	usd
CY2023Q2	us-gaap	Liabilities Liabilities	5509715	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8540408	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	166666667	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	166666667	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18376771	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18376771	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18288571	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18288571	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	18377	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	18289	usd
CY2023Q2	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1741397	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1214398	shares
CY2023Q2	us-gaap	Treasury Stock Value TreasuryStockValue	1741	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1214	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	173049784	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	172785800	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-57251261	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-46692098	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	115815159	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	126110777	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	121324874	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	134651185	usd
CY2023Q2	us-gaap	Revenues Revenues	13818166	usd
CY2022Q2	us-gaap	Revenues Revenues	13978665	usd
	us-gaap	Revenues Revenues	26821076	usd
	us-gaap	Revenues Revenues	27710195	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	5993145	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	4988716	usd
	us-gaap	Cost Of Revenue CostOfRevenue	11562766	usd
	us-gaap	Cost Of Revenue CostOfRevenue	10618574	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	7825021	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	8989949	usd
	us-gaap	Gross Profit GrossProfit	15258310	usd
	us-gaap	Gross Profit GrossProfit	17091621	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12242128	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12320362	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26274669	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	23711597	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	464761	usd
CY2022Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	578117	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	928695	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1049656	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	12706889	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	12898479	usd
	us-gaap	Operating Expenses OperatingExpenses	27203364	usd
	us-gaap	Operating Expenses OperatingExpenses	24761253	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4881868	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3908530	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11945054	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7669632	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	720419	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	23816	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1385891	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	23820	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4161449	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3884714	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10559163	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7645812	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-4161449	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3884714	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10559163	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7645812	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16992100	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18122500	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17043793	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18000958	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16992100	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18122500	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17043793	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18000958	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	126110777	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	1466694	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	2913809	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	40606	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-170400	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-6397714	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	123963772	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	1654770	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1848353	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	105100	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-72961	usd
CY2023Q2	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	7522426	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-4161449	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	115815159	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	131379717	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	905744	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	2268354	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	258128	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3761098	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	131050845	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	1336810	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	2688513	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	572347	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	9374455	usd
CY2022Q2	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	321054	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3884714	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	140817202	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10559163	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7645812	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	928695	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1049656	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7883626	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7199421	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	238748	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	98727	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3635420	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5969009	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1771899	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1266478	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-732200	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	64232	usd
	oprx	Increase Decrease In Revenue Share Payable IncreaseDecreaseInRevenueSharePayable	-1268313	usd
	oprx	Increase Decrease In Revenue Share Payable IncreaseDecreaseInRevenueSharePayable	-2001379	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-1096881	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-1263971	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	287478	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-347989	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2454489	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4388372	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	48556	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	41335	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	109501032	usd
	oprx	Redemptions Of Heldtomaturity Investments RedemptionsOfHeldtomaturityInvestments	-112501021	usd
	us-gaap	Payments To Acquire Additional Interest In Subsidiaries PaymentsToAcquireAdditionalInterestInSubsidiaries	2000000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	3068	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	145257	usd
	us-gaap	Payments For Software PaymentsForSoftware	1274150	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1674215	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2186592	usd
	oprx	Reduction Of Evince Med Purchase Price For Amounts Previously Paid ReductionOfEvinceMedPurchasePriceForAmountsPreviouslyPaid	243361	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	-7522426	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	-321054	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	145706	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	830474	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-7620081	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	509420	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8400355	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2711200	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18208685	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84681770	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9808330	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	87392970	usd
	us-gaap	Stock Issued1 StockIssued1	708334	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	9374455	usd
	oprx	Us Healthcare Providers Percentage USHealthcareProvidersPercentage	0.60	pure
	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	95108	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	226819	usd
CY2023Q2	us-gaap	Accumulated Capitalized Interest Costs AccumulatedCapitalizedInterestCosts	1300000	usd
CY2022Q2	us-gaap	Accumulated Capitalized Interest Costs AccumulatedCapitalizedInterestCosts	0	usd
CY2023Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	2975040	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	3582735	usd
CY2023Q2	us-gaap	Deferred Revenue DeferredRevenue	451787	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	164309	usd
CY2022Q4	us-gaap	Mineral Properties Gross MineralPropertiesGross	164309	usd
CY2021Q4	us-gaap	Mineral Properties Gross MineralPropertiesGross	1389907	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-8778893	usd
CY2022Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-6013181	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	9349724	usd
CY2022Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	5916318	usd
CY2023Q1	us-gaap	Mineral Properties Gross MineralPropertiesGross	735140	usd
CY2022Q1	us-gaap	Mineral Properties Gross MineralPropertiesGross	1293044	usd
CY2023Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-9619380	usd
CY2022Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-7373802	usd
CY2023Q2	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	9336027	usd
CY2022Q2	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	7122677	usd
CY2023Q2	us-gaap	Mineral Properties Gross MineralPropertiesGross	451787	usd
CY2022Q2	us-gaap	Mineral Properties Gross MineralPropertiesGross	1041919	usd
CY2023Q2	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	13818166	usd
CY2022Q2	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	13978665	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	26821076	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	27710195	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	49472	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	49747	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	8340	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	21899	usd
	us-gaap	Lease Cost LeaseCost	57812	usd
	us-gaap	Lease Cost LeaseCost	71646	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	10170	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5085	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	15255	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1236	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	14019	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y8M12D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.045	pure
CY2023Q2	us-gaap	Lease Deposit Liability LeaseDepositLiability	44708	usd
CY2022Q2	us-gaap	Lease Deposit Liability LeaseDepositLiability	45599	usd
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	49359	usd
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	52168	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	49472	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	52662	usd
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	166666667	shares
CY2023Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.001
CY2023Q2	us-gaap	Common Stock Shares Held In Employee Trust Shares CommonStockSharesHeldInEmployeeTrustShares	1741397	shares
CY2022Q4	us-gaap	Common Stock Shares Held In Employee Trust Shares CommonStockSharesHeldInEmployeeTrustShares	1214398	shares
	oprx	Shares Of Common Stock Issued SharesOfCommonStockIssued	10000	shares
CY2023Q1	oprx	Shares Of Common Stock Issued SharesOfCommonStockIssued	9668	shares
	oprx	Gross Proceeds Of Common Stock Amount GrossProceedsOfCommonStockAmount	105100	usd
	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	243361	usd
CY2022Q1	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	13627	shares
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	240741	shares
	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	9374455	usd
CY2023Q2	us-gaap	Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased	526999	shares
CY2023Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	7522426	usd
CY2022Q4	us-gaap	Common Stock Other Value Outstanding CommonStockOtherValueOutstanding	20000000	usd
CY2022	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1214398	shares
CY2022	us-gaap	Insurance Commissions InsuranceCommissions	20021830	usd
	oprx	Remaining Expenses RemainingExpenses	12254201	usd
	oprx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2	P1Y10M20D
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	309383	usd
	oprx	Restricted Stock Granted Remains Value RestrictedStockGrantedRemainsValue	13252855	usd
	oprx	Remains To Be Recognized Over A Period RemainsToBeRecognizedOverAPeriod	P2Y3D
CY2023Q2	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	86685	shares
CY2023Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	161698	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	2500000
CY2021Q4	oprx	Marketbased Restricted Stock Units MarketbasedRestrictedStockUnits	182398	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	1900000	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	-4161449	usd
	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	-3884714	usd
	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	-10559163	usd
	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	-7645812	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16992100	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18122500	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17043793	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18000958	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16992100	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18122500	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17043793	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18000958	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19824	shares
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	156018	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24923	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	176996	shares
CY2023Q2	oprx	Unvested Restricted Stock Unit Awards UnvestedRestrictedStockUnitAwards	24922	shares
CY2022Q2	oprx	Unvested Restricted Stock Unit Awards UnvestedRestrictedStockUnitAwards	63541	shares
	oprx	Unvested Restricted Stock Unit Awards UnvestedRestrictedStockUnitAwards	24922	shares
	oprx	Unvested Restricted Stock Unit Awards UnvestedRestrictedStockUnitAwards	77221	shares
CY2023Q2	oprx	Weighted Average Number Of Shares Total WeightedAverageNumberOfSharesTotal	44746	shares
CY2022Q2	oprx	Weighted Average Number Of Shares Total WeightedAverageNumberOfSharesTotal	219559	shares
	oprx	Weighted Average Number Of Shares Total WeightedAverageNumberOfSharesTotal	49845	shares
	oprx	Weighted Average Number Of Shares Total WeightedAverageNumberOfSharesTotal	254217	shares
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	21500000	usd
	oprx	Obligated Term Of Lease ObligatedTermOfLease	5800	usd
CY2023Q2	oprx	Obligated Term Of Lease ObligatedTermOfLease	2800	usd
CY2023Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	3500	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2022Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation		usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2022Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation		usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		usd
	oprx	Redemptions Of Heldtomaturity Investments RedemptionsOfHeldtomaturityInvestments		usd
	us-gaap	Payments To Acquire Additional Interest In Subsidiaries PaymentsToAcquireAdditionalInterestInSubsidiaries		usd
	us-gaap	Payments For Software PaymentsForSoftware		usd
	oprx	Reduction Of Evince Med Purchase Price For Amounts Previously Paid ReductionOfEvinceMedPurchasePriceForAmountsPreviouslyPaid		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q2	oprx	Effect Of Dilutive Stock Options Warrants And Stock Grants EffectOfDilutiveStockOptionsWarrantsAndStockGrants		shares
	oprx	Effect Of Dilutive Stock Options Warrants And Stock Grants EffectOfDilutiveStockOptionsWarrantsAndStockGrants		shares
	oprx	Effect Of Dilutive Stock Options Warrants And Stock Grants EffectOfDilutiveStockOptionsWarrantsAndStockGrants		shares
	oprx	Effect Of Dilutive Stock Options Warrants And Stock Grants EffectOfDilutiveStockOptionsWarrantsAndStockGrants		shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001448431

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001213900-23-067120-index-headers.html	Edgar Link	pending
0001213900-23-067120-index.html	Edgar Link	pending
0001213900-23-067120.txt	Edgar Link	pending
0001213900-23-067120-xbrl.zip	Edgar Link	pending
f10q0623ex31-1_optimizerx.htm	Edgar Link	pending
f10q0623ex31-2_optimizerx.htm	Edgar Link	pending
f10q0623ex32-1_optimizerx.htm	Edgar Link	pending
f10q0623_optimizerx.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
oprx-20230630.xsd	Edgar Link	pending
oprx-20230630_cal.xml	Edgar Link	unprocessable
oprx-20230630_def.xml	Edgar Link	unprocessable
oprx-20230630_lab.xml	Edgar Link	unprocessable
oprx-20230630_pre.xml	Edgar Link	unprocessable
f10q0623_optimizerx_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OPRX
OptimizeRx Corp Stock $oprx

2023 Q3 Form 10-Q Financial Statement

#000121390023067120 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPRX OptimizeRx Corp Stock $oprx

2023 Q3 Form 10-Q Financial Statement

#000121390023067120 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPRX
OptimizeRx Corp Stock $oprx